43 results
PRE 14A
GTHX
G1 Therapeutics Inc
12 Apr 24
Preliminary proxy
4:12pm
the benefit of trilaciclib in reducing ADC-related adverse events, indicated possible long-term survival trends, and will help to inform future development … is committed to maintaining sound corporate governance practices and creating long-term stockholder value. We highlight some of our corporate governance
8-K
EX-99.1
bhc3kkci7
28 Feb 24
Results of Operations and Financial Condition
6:35am
8-K
EX-99.1
28v3h
8 Jan 24
Results of Operations and Financial Condition
6:30am
8-K
EX-99.1
0mcomk
2 Aug 23
Results of Operations and Financial Condition
6:50am
8-K
EX-1.1
k3g90nl5619daqahk
18 Nov 22
G1 Therapeutics Announces Pricing of Offering of Common Stock
8:00pm
424B5
os0fui8zsg0 z27t
18 Nov 22
Prospectus supplement for primary offering
7:37pm
424B5
89v12mr0i pntx4u1
17 Nov 22
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
99jw 26rfpxy
2 Nov 22
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
6:45am